CLDX Celldex Therapeutics Inc.

5.92
-0.07  -1%
Previous Close 5.99
Open 5.97
Price To Book 0.56
Market Cap 68066408
Shares 11,497,704
Volume 236,662
Short Ratio
Av. Daily Volume 358,092

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2 data due 1Q 2019.
CDX-3379
Recurrent/metastatic head and neck squamous cell cancer
Phase 1/2 initiated July 2016. Phase 1 enrollment ongoing.
CDX-014
Renal cell carcinoma (RCC) - cancer
Phase 1/2 data presented November 17, 2018 at the Society for Neuro-oncology (SNO) Meeting.
Varlilumab and nivolumab
Solid tumors - cancer
Noted March 14, 2017 that development will not be advanced to Phase 2
Varlilumab and atezolizumab (anti-PDL1)
Renal cell carcinoma (RCC) cancer
Noted March 14, 2017 that development will not be advanced to Phase 2
Varlilumab and sunitinib (Sutent)
Clear cell renal cell carcinoma (CC-RCC) cancer
Phase 1/2 commenced April 2016.
Glembatumumab vedotin
Squamous cell lung cancer
Trial discontinued early March 2016 as unlikely to meet primary endpoint
CDX-110 rindopepimut - ACT IV
Cancer- glioblastoma multiforme (GBM) front line
Phase 2b data released April 16, 2018 - primary endpoint not met.
Glembatumumab vedotin
Metastatic triple negative breast cancers that overexpress gpNMB
Phase 2 continues to enroll. Glembatumumab vedotin and varlilumab arm data released at SITC November 2017.
Glembatumumab vedotin, varlilumab, Opdivo or Keytruda
Cancer - melanoma
Phase 2 presentation at AACR April 15, 2018.
CDX-301
Non-small Cell Lung Cancer (NSCLC)
Phase 1 updated data 1H 2019.
CDX-1140
Solid tumors

Latest News

  1. Celldex Therapeutics (CLDX) Stock Sinks As Market Gains: What You Should Know
  2. Analysis: Positioning to Benefit within Applied Materials, MRC Global, Meritor, Celldex Therapeutics, Quaker Chemical, and Cubic — Research Highlights Growth, Revenue, and Consolidated Results
  3. The Zacks Analyst Blog Highlights: BioDelivery, Cytokinetics, Celldex, Aduro and Aeterna
  4. 5 Tiny Biotech Stocks With Superb Growth Potential
  5. The Celldex Reverse Stock Split: What Investors Need To Know
  6. Biotech Stocks To Watch
  7. Celldex Therapeutics Announces Reverse Stock Split
  8. 4 Healthcare Stocks The Market is Watching on Tuesday (2/5/19)
  9. Biotech Stocks to Watch
  10. These 4 Tech Stocks Could Set February Highs
  11. Cannabis and Biotech Stocks that Could Explode
  12. Best Ways to Play Biotech Rally
  13. A Biotech Play You Can't Afford To Miss
  14. Here's Why Celldex Therapeutics Sank on Friday
  15. Why Celldex Therapeutics Is Jumping Today
  16. Analysis: Positioning to Benefit within Celldex Therapeutics, InnSuites Hospitality Trust, Keryx Biopharmaceuticals, EMX Royalty, FTE Networks, and Xinyuan Real Estate — Research Highlights Growth, Revenue, and Consolidated Results
  17. Celldex (CLDX) Q3 Earnings Beat Estimates, Revenues Miss
  18. Celldex Presents Promising Interim Data from Phase 1 Study of Differentiated CD40 Agonist CDX-1140 at the Society for Immunotherapy of Cancer’s 33rd Annual Meeting
  19. Here's Why Celldex Therapeutics, Inc. Surged on Thursday